Leukaemia Trial, Recruiting NCT06297161 Sponsor: Pfizer Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT06297161
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are currently being treated with Bosulif, or who are about to start treatment with Bosulif, as part of their normal medical care (including those who started Bosulif within the past year before signing consent)
  • People who have signed and dated a consent form, confirming they have been told about all relevant aspects of the study (a legal representative may sign on behalf of the patient if needed)

Who may not be able to join:

  • People for whom Bosulif is listed as unsuitable or unsafe according to the official product information in their country
  • People who do not agree to allow Pfizer and its partner companies to use their personal information for the study (or whose legal representative does not agree on their behalf)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
20 January 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of AEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov